|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA181050-04
|
|
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN
|
PULSIPHER, MICHAEL
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
CA
|
$90,772
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA187412-03
|
|
Impact of primary tumor development stage on prognosis and outcome in B-ALL
|
CARLSON, CHRISTOPHER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$100,931
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5U13ES026496-02
|
|
Childhood Leukemia International Consortium Scientific Annual Meetings
|
METAYER, CATHERINE
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$15,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA132640-16
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
GA
|
$270,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA190964-03
|
|
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$544,106
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA191077-03
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
KOLB, EDWARD
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
DE
|
$312,244
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA195356-02
|
|
Role of ThPOK in HSC Maintenance and Leukemogenesis
|
KAPPES, DIETMAR
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$199,013
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA194829-03
|
|
Metabolic regulation of T-ALL cellular proliferation and lifespan
|
RATHMELL, JEFFREY
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$204,885
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R35CA197695-01A1
|
|
Translating genomic discoveries to improved outcomes for high risk acute leukemia
|
MULLIGHAN, CHARLES
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$1,071,276
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA195519-02
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$272,213
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA201184-02
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$554,107
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA072669-20
|
|
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML
|
BLAZAR, BRUCE
|
UNIVERSITY OF MINNESOTA
|
MN
|
$294,076
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA169784-04
|
|
Genetic Dissection of Acute Myeloid Leukemia.
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$355,993
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172408-04
|
|
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies
|
YANG, FENG-CHUN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$318,513
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA174683-04
|
|
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia
|
BHATIA, SMITA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$606,475
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA182528-05
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
OH
|
$336,114
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R00CA181500-04
|
|
The Role of Protein Tyrosine Phosphate PRL3 in Leukemia Development
|
BLACKBURN, JESSICA
|
UNIVERSITY OF KENTUCKY
|
KY
|
$248,999
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA196330-02
|
|
Investigating the potential role of NADPH oxidase 2 in regulating the biology of leukemic stem cells
|
ADANE, BINIAM
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$29,728
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL117976-04
|
|
Epithelial mechanisms of inducible resistance to AML-associated pneumonia
|
EVANS, SCOTT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$400,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA167708-05
|
|
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics
|
GRANT, STEVEN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$284,794
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA194058-02
|
|
Painted erythrocyte carriers for therapy of acute myeloid leukemia
|
SIMBERG, DIMITRI
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$352,151
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA185301-03
|
|
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
OH
|
$352,275
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA201230-02
|
|
The role of H3K79 methylation in IDH-mutant leukemia
|
BERNT, KATHRIN
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$10,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA090668-14
|
|
FLT3 Tyrosine Kinase Inhibitors as Therapy for Leukemia
|
SMALL, DONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$291,600
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA142665-07
|
|
Glucocorticoids in Lymphoblastic Leukemia
|
RELLING, MARY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$487,994
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA181340-04
|
|
Targeting Chromatin Modifications in Leukemia with Trisomy 21
|
LANE, ANDREW
|
DANA-FARBER CANCER INST
|
MA
|
$155,991
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL130034-02
|
|
The Cebpa Enhancer in Normal Hematopoiesis and Progression to AML
|
FRIEDMAN, ALAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$405,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F30CA183507-04
|
|
Cytotoxicity of MLN4924 in Acute Myeloid Leukemia
|
KNORR, KATHERINE
|
MAYO CLINIC ROCHESTER
|
MN
|
$23,878
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172398-05
|
|
The role of ETV6 in T-cell acute lymphoblastic leukemia
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$332,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA183623-03
|
|
Pediatric Cancer Salvia Biorepository
|
GRAHAM, DAVID
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$245,885
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA173636-05
|
|
Role of TET2 mutations in malignant transformation and acute myeloid leukemia
|
LEVINE, ROSS
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$639,626
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F30CA183497-04
|
|
Modeling Transformation: Myeloproliferative Neoplasms to Acute Myeloid Leukemia
|
MCKENNEY, ANNA
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$49,044
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172268-05
|
|
The role of inhibitory receptors in leukemia development
|
ZHANG, CHENGCHENG
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$329,925
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA201225-02
|
|
Leukemia Specific Splice Isoforms as Neo-Antigens for T-Cell Immunotherapy
|
ARMISTEAD, PAUL
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$500,397
|
|
Childhood Leukemia
|
2017
|
NCI
|
2P30CA006516-52
|
5399
|
Program 4: Leukemia
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$43,922
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA211044-01
|
|
Off-the-shelf engineered NK cells for the treatment of AML
|
REZVANI, KATY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA164024-05
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$319,474
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA192822-03
|
|
Differential Regulation of PI3KC2beta by Ras Protooncogenes In Acute Myeloid Leukemia
|
SMITH, RUSSELL
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$23,996
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA211614-01
|
|
Targeting TET1 signaling to treat acute myeloid leukemia
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
OH
|
$430,865
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL117737-18
|
|
Microchimerism as AlloImmunity
|
NELSON, J.
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$477,844
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA211963-01
|
|
Ionizing radiation induced hematological malignancies
|
ZHOU, DAOHONG
|
UNIV OF ARKANSAS FOR MED SCIS
|
AR
|
$355,340
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA211711-01
|
|
APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY
|
DRULEY, TODD
|
WASHINGTON UNIVERSITY
|
MO
|
$388,615
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA212649-01
|
|
Personalized vaccine for patients with AML
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$739,429
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA211996-01
|
|
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
|
CHOW, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$742,626
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA213131-01
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$428,441
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA213138-01
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
MÜSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$395,738
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA192924-03
|
|
CSF2 receptor mediated actions in t(8;21) leukemia
|
ZHANG, DONG-ER
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$343,706
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA142874-07
|
|
Targeting PML for Leukemia Therapy
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$465,791
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172040-05
|
|
Microenvironment-Leukemia Communication Through Lectins
|
HEISTERKAMP, NORA
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
CA
|
$336,150
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
1K08HL135434-01
|
|
Targeting SETBP1 in Myeloproliferative Disorders
|
STIEGLITZ, ELLIOT
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$179,928
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F30CA186466-03
|
|
Role of GSK3beta Subcellular Localization in AML Stemness
|
IGNATZ-HOOVER, JAMES
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$29,040
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA166280-05
|
|
Therapeutic Targeting of Leukemia-Microenvironmental Interactions
|
CALVI, LAURA
|
UNIVERSITY OF ROCHESTER
|
NY
|
$318,513
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P30CA021765-38
|
6702
|
Hematalogical Malignancies
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$695,188
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P30CA021765-38
|
6709
|
Early Phase Clinical Research Support
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$256,191
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P30CA021765-38
|
6716
|
Transdisciplinary Collaboration and Coordination
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$319,535
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA194057-03
|
|
Metabolic pathways in leukemia
|
SCHUETZ, JOHN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$410,606
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA195642-03
|
|
Triad1 regulates myelopoiesis and functions as a leukemia suppressor
|
EKLUND, ELIZABETH
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$353,419
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA076167-14
|
|
Genetic Analysis of Myeloproliferative Disease
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
GA
|
$307,800
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA188520-03
|
|
Genome maintenance by Hdacs1,2 and their inhibition for Pre-B leukemia therapy
|
BHASKARA, SRIVIDYA
|
UNIVERSITY OF UTAH
|
UT
|
$340,838
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA204044-01A1
|
|
Regulation of TAL1/SCL in T-Cell Leukemia
|
HUANG, SUMING
|
UNIVERSITY OF FLORIDA
|
FL
|
$350,674
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA166429-06
|
|
Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$384,342
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
1R01GM118578-01A1
|
|
Genetics-guided Individualization of Thiopurine Therapy
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$579,917
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172387-05
|
|
Polysomy 21 in Acute Lymphoblastic Leukemia
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
MA
|
$352,946
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA174793-05
|
|
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia
|
VAKOC, CHRISTOPHER
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$557,762
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA190843-03
|
|
A Label-Free, Point-of-Care Platform to Diagnose Acute Promyelocytic Leukemia
|
SOHN, LYDIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$311,458
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA204979-01A1
|
|
Mechanisms of inv(16) acute myeloid leukemia
|
CASTILLA, LUCIO
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$426,803
|
|
Childhood Leukemia
|
2017
|
NCI
|
2R01CA158073-06A1
|
|
The Role of ATM in Suppression of Lymphomas
|
ZHA, SHAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$380,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA193842-03
|
|
Characterizing MSI2 in leukemia
|
KHARAS, MICHAEL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$414,827
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA187004-03
|
|
Targeting MLL3 histone methyltransferase
|
DOU, YALI
|
UNIVERSITY OF MICHIGAN
|
MI
|
$354,563
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA205912-02
|
|
Mediator Kinases and AML Cell Proliferation
|
TAATJES, DYLAN
|
UNIVERSITY OF COLORADO
|
CO
|
$172,855
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA178454-05
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
OH
|
$327,850
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA163452-05
|
|
Novel lysine deacetylase 6 Hsp domain inhibitors against AML
|
CHOU, CHUNG-JEN JAMES
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$310,213
|
|
Childhood Leukemia
|
2017
|
NCI
|
1K08CA201591-01A1
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$169,560
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA151898-07
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
MA
|
$392,969
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA176091-05
|
|
Crenolanib and ponatinib for the treatment of FLT3 mutant AML
|
SHAH, NEIL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$328,888
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA201496-02
|
|
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$463,530
|
|
Childhood Leukemia
|
2017
|
NICHD
|
1R21HD087760-01A1
|
|
Targeting SHP2 phosphatase for chemoprevention of leukemic progression in Noonan syndrome
|
QU, CHENG-KUI
|
EMORY UNIVERSITY
|
GA
|
$195,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA204308-02
|
|
Modulating signaling pathways in endothelial cells to abate leukemic progression.
|
BUTLER, JASON
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$383,445
|
|
Childhood Leukemia
|
2017
|
NCI
|
5U01CA176063-04
|
|
ARID5B and disparities of childhood leukemia
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$368,510
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA193235-03
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$462,191
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA197441-02
|
|
Unraveling the Function of RNA-Binding proteins in B-lympoblastic Leukemia
|
RAO, DINESH
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$200,970
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K99CA197498-03
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
CHEN, CHUN-WEI
|
DANA-FARBER CANCER INST
|
MA
|
$154,058
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA171338-05
|
|
Novel Targeted Therapy for AML
|
BHALLA, KAPIL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$332,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5UM1CA183730-04
|
|
Collaborative Human Tissue Network (CHTN)
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$774,914
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA190661-02
|
|
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
|
STIREWALT, DEREK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$573,343
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA205936-02
|
|
SIRT5 as a Therapeutic Target in Acute Myeloid Leukemia
|
DEININGER, MICHAEL
|
UNIVERSITY OF UTAH
|
UT
|
$164,620
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA205644-02
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$202,439
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA206210-02
|
|
Therapeutic targeting of glutamine metabolism in MDS
|
KONOPLEVA, MARINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$474,750
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA173852-04
|
|
Role of p21 activated kinase in Leukemogenesis
|
KAPUR, REUBEN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$323,700
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R33CA191143-03
|
|
Single cell growth assay for residual cells in acute lymphoblastic leukemia
|
MANALIS, SCOTT
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$450,496
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA204734-02
|
|
Determining the Role of BCOR Mutations in Myeloid Malignancies
|
LINDSLEY, ROBERT
|
DANA-FARBER CANCER INST
|
MA
|
$176,970
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R41CA213690-01
|
|
AML-MutationCounter, a tool to detect residual and recurrent leukemia
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
NC
|
$220,087
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R44CA213595-01
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
NC
|
$798,225
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA102031-12
|
|
Pharmacological modulation of epigenetic changes in AML
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$342,107
|
|
Childhood Leukemia
|
2017
|
NCI
|
1F30CA213878-01
|
|
Co-Evolution of the CD8+ T Cell Repertoire and AML In the Setting of Immunotherapy
|
GEORGE, JASON
|
RICE UNIVERSITY
|
TX
|
$49,044
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
1F31HL136107-01
|
|
Function of the Ubiquitin-Specific Peptidase 22 (USP22) in Acute Myeloid Leukemia
|
MELO-CARDENAS, JOHANNA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$38,255
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7522
|
Genomics of AML Clonality
|
LEY, TIMOTHY
|
WASHINGTON UNIVERSITY
|
MO
|
$328,402
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7523
|
Genomics of AML Relapse
|
DIPERSIO, JOHN
|
WASHINGTON UNIVERSITY
|
MO
|
$330,341
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7524
|
Genomics of Familial MDS/AML
|
GRAUBERT, TIMOTHY
|
WASHINGTON UNIVERSITY
|
MO
|
$339,464
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7525
|
Genomics of Teatment-Related AML
|
LINK, DANIEL
|
WASHINGTON UNIVERSITY
|
MO
|
$334,581
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7526
|
Clinical Database
|
WESTERVELT, PETER
|
WASHINGTON UNIVERSITY
|
MO
|
$258,322
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7527
|
Specimen Acquisition, Genomic, Transcriptomic and Epigenetic Profilling
|
PAYTON, JACQUELINE
|
WASHINGTON UNIVERSITY
|
MO
|
$212,765
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7528
|
Sequencing and Integrated Analysis of AML Genomes
|
WILSON, RICHARD
|
WASHINGTON UNIVERSITY
|
MO
|
$986,260
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P01CA101937-14
|
7529
|
Administration
|
LEY, TIMOTHY
|
WASHINGTON UNIVERSITY
|
MO
|
$127,287
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA176803-03
|
|
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
|
PAN, CHONG-XIAN
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$359,138
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA185062-04
|
|
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
MN
|
$312,304
|
|
Childhood Leukemia
|
2017
|
NIAID
|
1R21AI129426-01
|
|
Connecting Epigenetic Regulator MLL1 to ERK and Survival Signaling in B cells
|
ERNST, PATRICIA
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$228,355
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL131444-02
|
|
The role of EVI1-induced hypermethylation in leukemogenesis.
|
QIAN, ZHIJIAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$399,750
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA175353-04
|
|
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu
|
ROBINS, HARLAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$648,389
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA174750-04
|
|
Inhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapy
|
CAPITINI, CHRISTIAN
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$178,740
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F30CA196244-03
|
|
The role of the aryl hydrocarbon receptor in natural killer cell development in normal and acute myeloid leukemia donors
|
SCOVILLE, STEVEN
|
OHIO STATE UNIVERSITY
|
OH
|
$49,044
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA194923-03
|
|
Long non-coding RNAs in hematopoiesis and blood malignancy
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$457,533
|
|
Childhood Leukemia
|
2017
|
NCI
|
5U54CA193419-03
|
7381
|
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer
|
LICHT, JONATHAN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$460,150
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA178030-04
|
|
Regulation of transcription and tumor suppression by MTG family members
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
TN
|
$364,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5U54CA193461-03
|
7298
|
Project 1: Clonal Dynamics Guiding Curative Therapies for Acute Myeloid Leukemia
|
SCADDEN, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$532,795
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA184419-02
|
|
Chemotherapy resistance induced by SETD2 loss in leukemia
|
MAR, BRENTON
|
DANA-FARBER CANCER INST
|
MA
|
$177,120
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA190509-03
|
|
The function of cyclin C in tumorigenesis
|
SICINSKI, PETER
|
DANA-FARBER CANCER INST
|
MA
|
$453,569
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL115145-05
|
|
Yes1 as a quiescence regulator in hematopoietic stem cells
|
MUKHERJEE, SIDDHARTHA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$400,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA181507-02
|
|
Analysis of TET2 function in acute leukemia
|
SHIH, ALAN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$180,036
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA175761-04
|
|
Function of the PR domain of the MDSI-EVI1 in MLL fusion protein leukemogenesis
|
PERKINS, ARCHIBALD
|
UNIVERSITY OF ROCHESTER
|
NY
|
$318,513
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5K08HL127269-03
|
|
Bone Marrow Microenvironmental Expression of Cytochrome P450 Enzymes
|
GHIAUR, GABRIEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$171,720
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA193776-03
|
|
Improving risk allocation and developing novel therapies for children with T-ALL
|
TEACHEY, DAVID
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$625,779
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL120724-03
|
|
Balanced signaling cues to guide cell transitions in the blood lineage continuum
|
ROOSE, JEROEN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$742,879
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA194552-03
|
|
RETARGETING AGENTS TO TREAT AML
|
DIPERSIO, JOHN
|
WASHINGTON UNIVERSITY
|
MO
|
$380,068
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA197991-02
|
|
Determining the Role of Metabolism in Resistance in Acute Myeloid Leukemia
|
PARDEE, TIMOTHY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$354,563
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA173877-05
|
|
Targeted Therapy for AML Stem Cells
|
BHALLA, KAPIL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$332,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA133379-09
|
|
The role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$381,375
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA132946-10
|
|
Pharmacogenomics of Ara-C in AML
|
LAMBA, JATINDER
|
UNIVERSITY OF FLORIDA
|
FL
|
$310,602
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA064140-24
|
|
Role of AML1-ETO in Acute Leukemia
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
TN
|
$353,250
|
|
Childhood Leukemia
|
2017
|
NCI
|
5U10CA180886-04
|
|
COG NCTN Network Group Operations Center
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$22,547,116
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA182284-05
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$346,525
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5F31GM116569-02
|
|
Developing an Artemis Nuclease Inhibitor to Potentially Treat Acute Lymphoblastic Leukemia
|
ESGUERRA, ZITADEL ANNE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$42,686
|
|
Childhood Leukemia
|
2017
|
NINDS
|
5R21NS095273-02
|
|
Modulating the Nucleopathy caused by FUS Mutants of ALS
|
HAYWARD, LAWRENCE
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$209,375
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA178765-05
|
|
Transcriptional regulatory mechanisms in B cell development and leukemogenesis
|
ROEDER, ROBERT
|
ROCKEFELLER UNIVERSITY
|
NY
|
$565,455
|
|
Childhood Leukemia
|
2017
|
NCI
|
1U01CA214116-01
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
WA
|
$1,374,609
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R25CA183725-03
|
|
Problem-Solving Skills Training for Clinicians Providing Psychosocial Care in Pediatric Oncology
|
SAHLER, OLLE JANE
|
UNIVERSITY OF ROCHESTER
|
NY
|
$301,523
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA098571-13
|
|
Molecular Mechanisms of eIF4E mediated transformation
|
BORDEN, KATHERINE
|
UNIVERSITY OF MONTREAL
|
CANADA
|
$256,369
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA090321-15
|
|
Role of Sialic Acid Modification in ALL Survival and Drug Resistance
|
HEISTERKAMP, NORA
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
CA
|
$266,069
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R00CA168996-05
|
|
The role of Jmjd1c in normal and leukemic hematopoiesis
|
ZHU, NAN
|
BLOODCENTER OF WISCONSIN, INC.
|
WI
|
$238,701
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA188269-04
|
|
Developing CRM1 inhibitors in AML
|
GARZON, RAMIRO
|
OHIO STATE UNIVERSITY
|
OH
|
$319,550
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA185058-04
|
|
Impact of low IL-10 levels at birth and leukemia risk
|
WIEMELS, JOSEPH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$606,390
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA203161-02
|
|
Targeting PARP and RAD52 to induce "dual synthetic lethality" in leukemia patients identified by gene expression and mutation profiling
|
SULLIVAN, KATHERINE
|
TEMPLE UNIV OF THE COMMONWEALTH
|
PA
|
$29,663
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172896-05
|
|
Investigating the mechanism of ITGA4/6-mediated chemoprotection of ALL cells
|
KIM, YONG-MI
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
CA
|
$335,154
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA173085-05
|
|
Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia
|
BRAUN, BENJAMIN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$328,888
|
|
Childhood Leukemia
|
2017
|
NCI
|
2P30CA006973-54
|
8084
|
Hematologic Malignancies and BMT Program - 02
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$55,302
|
|
Childhood Leukemia
|
2017
|
NCI
|
1P01CA214278-01
|
8888
|
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.
|
PORTER, DAVID
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$435,992
|
|
Childhood Leukemia
|
2017
|
NCI
|
1P01CA214278-01
|
5000
|
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
|
GILL, SAAR
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$266,231
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA205828-02
|
|
Examining the role of normal hematopoiesis in supporting incipient myelodysplasia
|
PERKINS, ARCHIBALD
|
UNIVERSITY OF ROCHESTER
|
NY
|
$167,475
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA166229-05
|
|
HISTONE H3 METHYLATION AND EPIGENOMICS IN ACUTE LEUKEMIA
|
WARTMAN, LUKAS
|
WASHINGTON UNIVERSITY
|
MO
|
$153,699
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA185687-03
|
|
Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging
|
SMITH-BINDMAN, REBECCA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$2,177,040
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P30CA013696-43
|
6105
|
Lymphoid Development and Malignancy Program
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$35,133
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P30CA013696-43
|
6127
|
Recruitment
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$95,447
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA191091-03
|
|
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia
|
KNOECHEL, BIRGIT
|
DANA-FARBER CANCER INST
|
MA
|
$177,120
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA175215-05
|
|
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer
|
RADICH, JERALD
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$579,042
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA214965-01
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
OH
|
$412,442
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA201069-02
|
|
Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia
|
OPFERMAN, JOSEPH
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$410,606
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R56CA215059-01
|
|
The Role of DLST in Leukemogenesis
|
FENG, HUI
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$376,294
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA190261-03
|
|
The impact of chromosome 17p lesions on leukemogeneis and therapy response
|
LOWE, SCOTT
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$402,371
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
1R01HL136504-01
|
|
TEMPORAL CHANGES IN MECHANISMS OF HSC SELF-RENEWAL AND MYELOID LEUKEMOGENESIS
|
MAGEE, JEFFREY
|
WASHINGTON UNIVERSITY
|
MO
|
$381,250
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA215504-01
|
|
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
|
THIRMAN, MICHAEL
|
UNIVERSITY OF CHICAGO
|
IL
|
$609,178
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA190815-03
|
|
REGULATORY MECHANISMS OF HOX GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA
|
SPENCER, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$166,298
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA057138-26
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$635,460
|
|
Childhood Leukemia
|
2017
|
NCI
|
5U01CA199000-03
|
|
Pediatric Preclinical Testing Consortium - Leukemia
|
LOCK, RICHARD
|
UNIVERSITY OF NEW SOUTH WALES
|
AUSTRA
|
$390,171
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA163926-05
|
|
Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia
|
GREEN, MICHAEL
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$347,563
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA036401-34
|
|
Pharmacogenomics of Childhood Leukemia ALL
|
EVANS, WILLIAM
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$726,540
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA201831-02
|
|
SFK-inhibitor enhancement of ATRA-mediated differentiation of APL
|
REDNER, ROBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$169,106
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
1K08HL136894-01
|
|
Hedgehog Signaling in the Progression of Myelodysplastic Syndromes
|
GONDEK, LUKASZ
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$171,720
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA169485-05
|
|
Targeting Leukemia with Memory CD8+ T cells Transduced to Express High-Affinity W
|
CHAPUIS, AUDE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$171,372
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA198089-03
|
|
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
|
CARROLL, MARTIN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$663,135
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA194256-03
|
|
Chimeric Antigen Receptor T cell Therapy for Acute Myeloid Leukemia (AML)
|
GILL, SAAR
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$167,832
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA201775-02
|
|
Targeting B cell activating factor receptor (BAFF-R) as a novel therapeutic strategy for drug resistant Acute Lymphoblastic Leukemia (ALL)
|
PARAMESWARAN, RESHMI
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$172,369
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA187318-03
|
|
Molecular understanding of cytokine-Ras signals in leukemic bone marrow
|
ROOSE, JEROEN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$353,777
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA189074-03
|
|
Small molecule CXCR4 modulators as molecular probes for studying AML
|
SCHILTZ, GARY
|
NORTHWESTERN UNIVERSITY
|
IL
|
$513,581
|
|
Childhood Leukemia
|
2017
|
NCI
|
2K12CA090433-16
|
|
Pediatric Oncology Clinical Research Training Program
|
POPLACK, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$810,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA104509-13
|
|
Molecular Mechanism of Leukemogenesis Involving AML1-ETO
|
ZHANG, DONG-ER
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$331,313
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R35CA197561-03
|
|
Molecular Pathogenesis of Acute Myeloid Leukemia
|
LEY, TIMOTHY
|
WASHINGTON UNIVERSITY
|
MO
|
$915,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA193478-02
|
|
Web-based Physical Activity Intervention for Children with ALL
|
NESS, KIRSTEN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$869,905
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA209829-02
|
|
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia
|
PAYNE, KIMBERLY
|
LOMA LINDA UNIVERSITY
|
CA
|
$360,547
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F30CA203292-02
|
|
Chromatin dysregulation generated by recurrent point mutation in histone methyltransferase, MMSET, drives progression of lymphoid malignancies
|
SWAROOP, ALOK
|
UNIVERSITY OF FLORIDA
|
FL
|
$38,371
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA202488-02
|
|
Unlocking the Therapeutic Potential of Retinoic Acid in Acute Myeloid Leukemia
|
SWORDS, RONAN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$166,931
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5P50GM115279-03
|
7544
|
CPML - Core A: Administrative Core
|
RELLING, MARY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$204,478
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5P50GM115279-03
|
7545
|
CPML - Core B: Cell & Molecular Core
|
CREWS, KRISTINE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$348,034
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5P50GM115279-03
|
7546
|
CPML - Core C: Bioinformatics & Biostatistical Core
|
ZHANG, JINGHUI
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$596,871
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5P50GM115279-03
|
7547
|
CPML - Project 1: Genome-wide Studies of ALL Response
|
MULLIGHAN, CHARLES
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$737,381
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5P50GM115279-03
|
7548
|
CPML - Project 2: Genome-wide Studies of ALL Drug Sensitivity
|
EVANS, WILLIAM
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$707,707
|
|
Childhood Leukemia
|
2017
|
NIGMS
|
5P50GM115279-03
|
7549
|
CPML - Project 3: Genome-wide Studies of Adverse Effects
|
RELLING, MARY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$369,780
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P30CA125123-11
|
8015
|
Pediatric Cancer Program (Project-007)
|
POPLACK, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$43,684
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA202296-02
|
|
HSC-Independent Mechanisms Underlying JMML
|
KAPUR, REUBEN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$205,538
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA216421-01
|
|
The cohesin complex as a tumor suppressor in myeloid leukemia
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$536,993
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA207086-01A1
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$326,540
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA216352-01
|
|
In Vivo Functional Analysis of Chromosome 7q22 Deletions in Myeloid Malignancies
|
SHANNON, KEVIN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$338,672
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R03CA186176-02
|
|
Targeting high fat diet-driven DNA hypermethylation for AML chemoprevention
|
LIU, SHUJUN
|
UNIVERSITY OF MINNESOTA
|
MN
|
$77,500
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA172443-04
|
|
Targeting NEDD8-Mediated Protein Turnover in AML
|
CAREW, JENNIFER
|
UNIVERSITY OF ARIZONA
|
AZ
|
$286,661
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA202390-02
|
|
PRMT1-mediated metabolic reprogramming in leukemia progression
|
ZHAO, XINYANG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$191,835
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
1R01HL132921-01A1
|
|
Mitotic failure in Fanconi anemia: mechanisms and role in carcinogenesis
|
NALEPA, GRZEGORZ
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$393,750
|
|
Childhood Leukemia
|
2017
|
NCI
|
2R01CA101774-15
|
|
Mechanisms of Leukemogenesis in Down Syndrome
|
CRISPINO, JOHN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$336,656
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA201235-01A1
|
|
Targeting the GFI1-LSD1 Axis in T-Cell Acute Lymphoblastic Leukemia
|
ENGEL, MICHAEL
|
UNIVERSITY OF UTAH
|
UT
|
$346,271
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA096899-12
|
|
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis
|
KELLIHER, MICHELLE
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$358,031
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA206322-02
|
|
Mechanism of the methyltransferase Prdm3 in MLL leukemogenesis
|
MCGLYNN, KELLY
|
UNIVERSITY OF ROCHESTER
|
NY
|
$44,044
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R21CA209229-02
|
|
Mechanism of Ikaros Tumor Suppression in progenitor B cell leukemia
|
SCHJERVEN, HILDE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$184,753
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA196045-03
|
|
The role of PRDM16 in Leukemia
|
CORRIGAN, DAVID
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$41,070
|
|
Childhood Leukemia
|
2017
|
NCI
|
1K08CA201611-01A1
|
|
DEFINING THE ROLE OF DOT1L IN DNMT3A-MUTANT LEUKEMIA
|
RAU, RACHEL
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$162,148
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA196658-02
|
|
A rapid spontaneous murine model of CN-AML
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$575,500
|
|
Childhood Leukemia
|
2017
|
NCI
|
1K99CA207731-01A1
|
|
Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia
|
THOMAS, DANIEL
|
STANFORD UNIVERSITY
|
CA
|
$173,448
|
|
Childhood Leukemia
|
2017
|
NCI
|
1K08CA201640-01A1
|
|
Developing differentiation therapy for the treatment of patients with acute myeloid leukemia
|
SYKES, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$169,268
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA187903-03
|
|
CHARACTERIZATION OF THE MOLECULAR INTERPLAY BETWEEN HOXA9 AND OGT IN ACUTE LEUKEMIA
|
RUAL, JEAN-FRANCOIS
|
UNIVERSITY OF MICHIGAN
|
MI
|
$354,563
|
|
Childhood Leukemia
|
2017
|
NCI
|
7R01CA201444-02
|
|
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia Microenvironment
|
MITTELMAN, STEVEN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$396,181
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R21CA216551-01
|
|
Targeting DNA Base Excision Repair in Acute Myeloid Leukemias
|
LLOYD, R.
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$200,970
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA196604-03
|
|
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia
|
CHIANG, MARK
|
UNIVERSITY OF MICHIGAN
|
MI
|
$354,563
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA187397-04
|
|
Exercise and QUality diet After Leukemia
|
TONOREZOS, EMILY
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$621,296
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA204231-01A1
|
|
Cohesin Mutations in Acute Myelogenous Leukemia
|
RAO, SRIDHAR
|
BLOODCENTER OF WISCONSIN, INC.
|
WI
|
$391,588
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA175026-04
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$379,294
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA175737-04
|
|
Perinatal immune development and risk of childhood acute lymphoblastic leukemia
|
WIEMELS, JOSEPH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$675,204
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R21CA208937-01A1
|
|
Mechanism-based approach to combine histone deacetylase inhibitors with PARP inhibitors for therapy in AML
|
RASSOOL, FEYRUZ
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$201,459
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R00CA188293-04
|
|
Exploring a new therapeutic approach through targeting epigenetic enzymes in ALL
|
NTZIACHRISTOS, PANAGIOTIS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$249,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA206338-02
|
|
Myc transcriptional regulation in T-ALL
|
FORSYTH, KATHERINE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$44,044
|
|
Childhood Leukemia
|
2017
|
NCI
|
5U01CA183030-04
|
|
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML
|
LIU, YANG
|
CHILDREN'S RESEARCH INSTITUTE
|
DC
|
$521,464
|
|
Childhood Leukemia
|
2017
|
RMAP
|
5K01ES026842-03
|
|
Connecting Single Cell Heterogeneity to Clinical Descriptors of Clonal Evolution in Acute Myeloid Leukemia
|
PAGUIRIGAN, AMY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$119,735
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA176624-04
|
|
Tsc1/mTOR axis in immune homeostasis and tumorigenesis
|
CHI, HONGBO
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$372,463
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL128173-03
|
|
Multiscale Modeling of Myelodysplastic Syndromes
|
COREY, SETH
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$729,676
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA193651-03
|
|
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL
|
GUTIERREZ, ALEJANDRO
|
BOSTON CHILDREN'S HOSPITAL
|
MA
|
$446,954
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA206463-02
|
|
Clonal Progression of Cancer Cells during Treatment of Acute Lymphoblastic Leukemia
|
CONTRERAS-TRUJILLO, HUMBERTO
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$43,477
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R00CA184411-05
|
|
Research career advancement: Role of the SIRT1 deacetylase in maintenance of FLT3
|
LI, LING
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$248,999
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K01CA188151-03
|
|
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML
|
OROZCO, JOHNNIE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$169,020
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R00CA181488-04
|
|
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
|
LOSMAN, JULIE
|
DANA-FARBER CANCER INST
|
MA
|
$249,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA187577-04
|
|
Investigating Resistance to FLT3 Inhibitors in AML
|
SMITH, CATHERINE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$175,808
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F30CA210518-02
|
|
Evaluation of Bruton’s Tyrosine Kinase and p110 delta in Mutant Shp2-Induced JMML
|
DENG, LISA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$36,469
|
|
Childhood Leukemia
|
2017
|
NCI
|
5P50CA100632-15
|
|
SPORE University of Texas M.D. Anderson Cancer Center SPORE-Leukemia
|
KANTARJIAN, HAGOP
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$2,300,000
|
|
Childhood Leukemia
|
2017
|
NHLBI
|
5R01HL130995-02
|
|
Germline mutations of PTPN11 (SHP-2) in the stem cell microenvironment
|
QU, CHENG-KUI
|
EMORY UNIVERSITY
|
GA
|
$390,000
|
|
Childhood Leukemia
|
2017
|
NCI
|
1F30CA217006-01
|
|
Analysis of the novel phenomenon of antibody-mediated fratricide in Acute Myeloid Leukemia
|
FATEHCHAND, KAVIN
|
OHIO STATE UNIVERSITY
|
OH
|
$39,139
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA188529-04
|
|
Genomic profiling and development of murine models of transformation of MPNs
|
RAMPAL, RAAJIT
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$178,200
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R35CA210030-02
|
|
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
MA
|
$1,046,441
|
|
Childhood Leukemia
|
2017
|
NCI
|
1F30CA217027-01
|
|
Investigating the role of miR-155 and the interferon response in FLT3-ITD+ AML
|
WALLACE, JARED
|
UNIVERSITY OF UTAH
|
UT
|
$40,644
|
|
Childhood Leukemia
|
2017
|
NCI
|
1F31CA216976-01
|
|
The Effect Of Cohesin Mutations In Hematologic Malignancies
|
MCNULTY, MAUREEN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$38,129
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA140729-07
|
|
Drug resistant pathways in relapsed acute lymphoblastic leukemia (ALL)
|
CARROLL, WILLIAM
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$454,699
|
|
Childhood Leukemia
|
2017
|
NIAMS
|
5R01AR054447-10
|
|
The Osteoblast as a Determinant of Leukemogenesis
|
KOUSTENI, STAVROULA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$341,711
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA138744-08
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
BAKER, SHARYN
|
OHIO STATE UNIVERSITY
|
OH
|
$343,388
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA195732-02
|
|
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
|
LICHT, JONATHAN
|
UNIVERSITY OF FLORIDA
|
FL
|
$348,844
|
|
Childhood Leukemia
|
2017
|
NCI
|
1R01CA217092-01
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$397,371
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5P50ES018172-08
|
5328
|
Core A - Administrative Core
|
METAYER, CATHERINE
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$170,439
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5P50ES018172-08
|
5329
|
Project 1 - In Utero Chemical Exposures, Immune Status, and Childhood Leukemia
|
METAYER, CATHERINE
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$184,021
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5P50ES018172-08
|
5330
|
Project 2 - Identifying In Utero Exposures that are Risk Factors for Childhood Leukemia
|
RAPPAPORT, STEPHEN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$176,369
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5P50ES018172-08
|
5331
|
Project 3 - Prenatal Exposures, Constitutive Genetics, DNA Methylation & Childhood Leukemia
|
WIEMELS, JOSEPH
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$168,610
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5P50ES018172-08
|
5332
|
Core B - Community Outreach and Translation Core
|
MILLER, MARK
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$87,541
|
|
Childhood Leukemia
|
2017
|
NIEHS
|
5P50ES018172-08
|
5333
|
Core C - Mouse Model Service Core
|
KOGAN, SCOTT
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$63,020
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F31CA192885-03
|
|
The Role of DDX41 in the Spliceosome and Myeloid Neoplasia
|
HIZNAY, JAMES
|
CLEVELAND CLINIC LERNER COM-CWRU
|
OH
|
$38,328
|
|
Childhood Leukemia
|
2017
|
NCI
|
1F31CA217140-01
|
|
Novel mechanisms and therapeutic strategies of refractory leukemia
|
MELGAR, KATELYN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$36,724
|
|
Childhood Leukemia
|
2017
|
NCI
|
5F32CA203049-02
|
|
Targeting PRL2 phosphatase in acute myeloid leukemia
|
NABINGER, SARAH
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$64,245
|
|
Childhood Leukemia
|
2017
|
NCI
|
5K08CA184418-04
|
|
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia
|
TASIAN, SARAH
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$169,657
|
|
Childhood Leukemia
|
2017
|
NCI
|
5R01CA181024-04
|
|
Prevention of bone loss after pediatric hematopoietic cell transplantation
|
SARAFOGLOU, KYRIAKIE
|
UNIVERSITY OF MINNESOTA
|
MN
|
$1
|
|
